Preventative Vaccine
Alzheimer's Disease (Prevention)
PreclinicalActive
Key Facts
About Abyssinia Biologics
Abyssinia Biologics is a preclinical-stage biotech developing highly selective monoclonal antibodies and a vaccine targeting toxic amyloid-beta oligomers for Alzheimer's disease. Founded in 2021 and operating with a virtual team, the company's platform aims to deliver greater clinical benefit with fewer side effects, such as ARIA, compared to plaque-clearing therapies. Its integrated strategy includes therapeutic, preventative, and diagnostic solutions, positioning it in the high-need, high-value neurodegenerative disease market, though it faces significant scientific, clinical, and competitive risks typical of early-stage CNS drug development.
View full company profileTherapeutic Areas
Other Alzheimer's Disease (Prevention) Drugs
| Drug | Company | Phase |
|---|---|---|
| Anti-Abeta active immunotherapy | AC Immune | Phase 2 |